Respiratory
Human Pharma Clinical Pipeline Respiratory therapeutic area
Search
Boehringer Ingelheim Advances Oncology Research
Boehringer Ingelheim Advances Its Oncology Research Program Through Innovative Partnerships
Ezabenlimab, PD-1 antibody
Ezabenlimab, PD-1 antibody
Facing Pulmonary Fibrosis
Steve Jones talks about his experience facing his pulmonary fibrosis diagnosis.
VSV-GP
VSV-GP
Congress Patient Benefit
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
CD137/FAP agonist
CD137/FAP agonist
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Nerandomilast (BI 1015550): PDE4B inhibitor
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Five facts everyone should know about heartworms
Heartworms are dangerous parasites that can infest pets through mosquito bites, causing serious illness. Here are five key facts we all should know about heartworms.
BI 764532: DLL3/CD3 T-cell engager
BI 764532: DLL3/CD3 T-cell engager
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
Obesity
Obesity
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
BI 764532: DLL3/CD3 T-cell engager | ep-NEC
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.